Co-Authors
This is a "connection" page, showing publications co-authored by ANUJA JHINGRAN and LOIS M RAMONDETTA.
Connection Strength
1.350
-
Eleven years: the long and winding road. Gynecol Oncol. 2007 Nov; 107(2):166-8.
Score: 0.304
-
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
Score: 0.110
-
Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7.
Score: 0.106
-
Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer. 2011 May 01; 117(9):1928-34.
Score: 0.094
-
Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecol Oncol. 2006 Nov; 103(2):547-53.
Score: 0.069
-
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11.
Score: 0.057
-
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed m?llerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36.
Score: 0.057
-
Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer. 2022 Sep 01; 22(1):945.
Score: 0.053
-
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
Score: 0.051
-
A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905.
Score: 0.048
-
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 02 22; 4(1):237.
Score: 0.048
-
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
Score: 0.045
-
Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):163-171.
Score: 0.044
-
Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244.
Score: 0.043
-
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121.
Score: 0.038
-
Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
Score: 0.030
-
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecol Oncol. 2010 Dec; 119(3):422-5.
Score: 0.023
-
Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
Score: 0.021
-
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
Score: 0.021
-
Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009 Mar; 200(3):288.e1-8.
Score: 0.021
-
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
Score: 0.019
-
Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
Score: 0.016
-
Malignant mixed M?llerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):786-96.
Score: 0.015
-
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
Score: 0.014